patient alzheimer disease plaque biogen chief executive george scangos said interview hard think reason data not representative actual activity drug higher doses greater effect safety tolerability considered acceptable company said big jump incidence amyloid related imaging abnormalities edema aria e higher doses patients gene associated highest risk developing alzheimer highest risk patients dropped trial higher rate aria e asymptomatic mild resolved time sandrock said imaging measure amyloid regions brain researchers found plaque levels virtually unchanged 26 54 weeks study placebo group patients received 3 milligrams kilogram weight 6 mg kg 10 mg kg aducanumab showed significant dose dependent increase plaque